Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07262255
NA

WATCHMAN FLX Pro European Registry

Sponsor: Boston Scientific Corporation

View on ClinicalTrials.gov

Summary

The WATCHMAN FLX Pro European registry is intended to gather real world clinical data for patients undergoing left atrial appendage closure (LAAC) with the WATCHMAN FLX™ Pro device. In a subregistry with approximately 300 patients, it is intended to use the VersaCross Connect™ LAAC Access Solution.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

1000

Start Date

2025-12-17

Completion Date

2028-09

Last Updated

2026-04-09

Healthy Volunteers

No

Interventions

DEVICE

Left atrial appendage closure

The WATCHMAN FLX Pro LAAC Technology is intended to prevent thrombus embolization from the left atrial appendage and reduce the risk of life-threatening bleeding events in adult patients with non-valvular atrial fibrillation who are eligible for anticoagulation therapy or who have a contraindication to anticoagulation therapy. The VersaCross Connect™ LAAC Access Solution is indicated for the percutaneous introduction of various types of cardiovascular catheters and guidewires to all heart chambers, including the left atrium via transseptal perforation / puncture.

Locations (7)

Rigshospitalet Copenhagen

Copenhagen, Denmark

Kath Krankenhaus St Johann Nepomuk

Erfurt, Germany

Asklepios Klinik Saint Georg

Hamburg, Germany

Asklepios Klinik Nord Heidberg

Hamburg, Germany

Hospital de Leon

León, Spain

Clinica Universidad de Navarra

Pamplona, Spain

University Hospital Basel

Basel, Switzerland